NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

depression

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

ONLY AVAILABLE IN PAID PLANS.

Originally reported by benzinga. Read more

Source: https://www.benzinga.com/pressreleases/26/01/g49900556/nrx-pharmaceuticals-nasdaq-nrxp-announces-70-000-patient-data-on-real-world-use-of-ketamine-for-tr